Save the Sound: Members of Arvinas helped preserve the Long Island Sound and Greater New Haven area by collecting over 287 pounds of trash, contributing to efforts to protect local wildlife and ...

Currently There Are More Than 50 PROTAC Drugs In Clinical Trials And Majority Are For Cancer As Per Recent Study By Kuick ...

First PROTAC Drug Is Expected To Enter The Market By 2027 Says Kuick In New StudyDelhi, Oct. 11, 2024 (GLOBE NEWSWIRE) -- ...

Many of the protein degradation products appeared as discrete cleavage products that are generated by calpain proteolysis. We assessed calpain activity and found it to be significantly increased.

【导读】蛋白水解靶向嵌合体（PROteolysis TArgeting Chimeras, PROTACs）被认为是下一个重磅疗法。然而，由于其固有的局限性，PROTACs的疗效经常受到组织穿透能力有限以及其作用部位的细胞内化不足的影响。10月18日 ...

Research over the last two decades has extended the paradigm of ATP- and ubiquitin-dependent proteasomal protein degradation by discovering that intrinsically unstructured proteins (IUPs) can be ...

Biotechnology Co. Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN) ligand coupled to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; ...

Despite past performance issues, Arvinas has a solid cash runway. Learn more about ARVN stock's potential and why a cautious ...

Nanjing Mingde New Drug Research Co. Ltd. has designed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a GTPase KRAS (G12D mutant ...

Killing breast cancer cells in a way that trains the immune system to recognize and destroy residual cancer cells could offer ...

Discover Booster Therapeutics' novel 20S proteasome activation approach to neurodegenerative diseases as it launches with $15 ...

The company is developing molecules that boost the ubiquitin-independent protein degradation activity of 20S proteasomes in ...